. Author manuscript; available in PMC: 2022 Apr 1.

Published in final edited form as: Am J Perinatol. 2019 Oct 10;38(5):469–476. doi: 10.1055/s-0039-1698457

Table 4.

Multivariable adjusted relative risk of ever receiving antiepileptic medication during the neonatal period. ^a

	Clinical Characteristics	aRR (95% CI)	P-value

Entire cohort	Female	1.01 (0.99, 1.04)	0.450
	Gestational Age
	<37	Reference
	≥37	1.11 (1.06, 1.16)	<0.0001
	Ischemic or thrombotic stroke	1.16 (1.11, 1.21)	<0.0001
	Intraventricular hemorrhage	1.24 (1.17, 1.31)	<0.0001
	Hypoxic ischemic encephalopathy	1.26 (1.21, 1.32)	<0.0001
	Other hemorrhagic stroke	1.11 (1.07, 1.15)	<0.0001
	Congenital brain abnormalities	1.02 (0.96, 1.07)	0.579
	Chromosomal abnormalities	0.94 (0.86, 1.04)	0.268

HTE + Cooling Subcohort	Female	1.01 (0.95, 1.07)	0.828
	Gestational Age
	<37	Reference
	≥37	0.98 (0.89, 1.07)	0.629
	Ischemic or thrombotic stroke	0.95 (0.78, 1.17)	0.627
	Intraventricular hemorrhage	1.09 (1.01, 1.19)	0.030
	Other hemorrhagic stroke	1.02 (0.97, 1.08)	0.448
	Congenital brain abnormalities	1.11 (1.07, 1.16)	<0.0001
	Chromosomal abnormalities	1.04 (0.97, 1.12)	0.271

Administered within the first 28 days of life.